Summary
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.
Official Title
The Four-Repeat Tauopathy Neuroimaging Initiative
Keywords
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP), CBD, CBS, CBGD, PSP, nfvPPA, oPSP, vPSP, o/vPSP, Corticobasal Degeneration, Corticobasal Syndrome, Cortocal-basal Ganglionic Degeneration, Progressive Supranuclear Palsy, Nonfluent Variant Primary Progressive Aphasia, Oligosymptomatic Progressive Supranuclear Palsy, Variant Progressive Supranuclear Palsy, Biomarker, Neuroimaging, MRI, PET, Tau, Oculomotor, Retinal Imaging, Paralysis, Aphasia, Primary Progressive Aphasia, Pick Disease of the Brain, Frontotemporal Dementia, Tauopathies, PSP & CBD